Evidence
Expert Rev Neurother. 2024 Sep 18:1-9. doi: 10.1080/14737175.2024.2402058. Online ahead of print.
ABSTRACT
INTRODUCTION: Alzheimer’s disease is the most common form of dementia worldwide. Aducanumab, a monoclonal antibody targeting amyloid-beta, became the first disease-modifying treatment for mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia and suggested that removing amyloid from the brain, especially in early AD, might make a difference in slowing cognitive decline.
AREAS COVERED: In this review, the authors outline aducanumab’s clinical efficacy as shown through key clinical trials and discuss its approval by the Food and Drug Administration under the accelerated pathway, which sparked both hope and controversy. We also discuss the importance of amyloid-related imaging abnormalities as a major side effect of aducanumab and all subsequent monoclonal antibodies targeting amyloid-beta.
EXPERT OPINION: Aducanumab, became the first monoclonal antibody that provided at least partial support for the amyloid hypothesis by demonstrating slowed cognitive decline by removing amyloid from the brain, although full FDA approval now seems unlikely due to discontinuation of its development. Its introduction raised awareness of ARIA, highlighted the significant costs and need for informed consent in treatment, and emphasized the importance of long-term, diverse, and combination therapy data for future AD treatments targeting amyloid and tau.
PMID:39291991 | DOI:10.1080/14737175.2024.2402058
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Profiling aducanumab as a treatment option for alzheimer’s disease: an overview of efficacy, safety and tolerability
🌐 90 Days
Evidence Blueprint
Profiling aducanumab as a treatment option for alzheimer’s disease: an overview of efficacy, safety and tolerability
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence